Vol 70, No 2 (2020)
Review paper
Published online: 2020-04-07

open access

Page views 584
Article views/downloads 518
Get Citation

Connect on Social Media

Connect on Social Media

Adjuvant radioiodine treatment in patients with thyroid cancer – current recommendations

Agnieszka Czarniecka1, Daria Handkiewicz-Junak2
DOI: 10.5603/NJO.2020.0015
Nowotwory. Journal of Oncology 2020;70(2):65-68.

Abstract

Radioactive iodine therapy (RAI) has been used in patients with differentiated thyroid cancers (DTC) for many decades. However, many changes in thyroid cancer treatment have been introduced for the last decade worldwide, mainly a tendency to deescalate both surgical and adjuvant treatment has been observed. This work summarizes current Polish guidelines for adjuvant radioiodine therapy compared to American Thyroid Association recommendations.

Article available in PDF format

View PDF Download PDF file

References

  1. Choudhury PS, Gupta M. Differentiated thyroid cancer theranostics: radioiodine and beyond. Br J Radiol. 2018; 91(1091): 20180136.
  2. Haugen BR, Haugen BR, Alexander EK, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016; 26(1): 1–133.
  3. Treglia G, Aktolun C, Chiti A, et al. EANM and the EANM Thyroid Committee. The 2015 Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the "evidence-based" refusal to endorse them by EANM due to the "not evidence-based" marginalization of the role of Nuclear Medicine. Eur J Nucl Med Mol Imaging. 2016; 43(8): 1486–1490.
  4. Jarząb B, Dedecjus M, Słowińska-Klencka D, et al. Guidelines of Polish National Societies Diagnostics and Treatment of Thyroid Carcinoma. 2018 Update. Endokrynol Pol. 2018; 69(1): 34–74.
  5. Luster M, Aktolun C, Amendoeira I, et al. European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium. Thyroid. 2019; 29(1): 7–26.
  6. Schlumberger M, Leboulleux S, Catargi B, et al. Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial. The Lancet Diabetes & Endocrinology. 2018; 6(8): 618–626.
  7. Dehbi HM, Mallick U, Wadsley J, et al. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial. Lancet Diabetes Endocrinol. 2019; 7(1): 44–51.



Nowotwory. Journal of Oncology